NCT06872359 - Evaluation of Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling | Crick

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Subject * Sex: male or female * Age: more than 18 years * Subject seeking an improvement of her/his face aspect with resorbable filler * The subjects must meet a criterion according to the treatment indication specific scale (Asher Face Volume Loss Scale (FVLS), Bazin Ptosis of the Lower part of the Face Scale (PLFS), temple hollow scale (THS), Wrinkle Severity Rating Scale (WSRS), Bazin Marionette Lines scale (MLS), Bazin Upper Lip Wrinkle Scale (ULWS), Rossi scale) * Subject having given their free, express, and informed consent * Subject psychologically able to understand the information related to the study, and to give their written informed consent * Subject affiliated to a health social security system * Women of childbearing potential should use a contraceptive method considered effective since at least 12 weeks and throughout the study * Women of childbearing potential must have a negative urinary pregnancy test on D0 Exclusion Criteria: * Pregnant or nursing woman or planning a pregnancy during the study. * Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship * Subject in a social or sanitary establishment * Subject participating to another clinical research or being in an exclusion period for a previous study * In France: subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study * Subject already included in another group of this study * Subject having received treatment with a laser, ultrasound or radiofrequency treatment, a dermabrasion, a surgery, a chemical peeling or any other procedure based on active dermal response on the face in the 6 previous months * Subject having received mesotherapy products or botulinum toxin in the same area in the 6 previous months * Subject having received resorbable filling product (e.g., hyaluronic acid) injections in the same area in the 12 previous months * Subject having received slowly resorbable filling product (e.g., calcium hydroxyapatite, polycaprolactone, polylactic acid) injections in the same area or resorbable threads in the 24 previous months * Subject having received injections of permanent products in the face (e.g., acrylate polymers, silicone, polytetrafluoroethylene) * Subject having received facial or cervico-facial lifting in the 24 previous months * Subject wearing skin support device (mesh, gold threads, permanent lifting threads) on the face * Subject with uncontrolled and/or recently recovered (\<6 months) depression or psychiatric disorders or any other disorder that may pose a health risk to the subject in the study and/or may have an impact on the study assessments * Subject with severe, ongoing and uncontrolled diseases such as malignancy or history of malignancy, type I diabetes, liver failure, renal failure, lung/heart disease, neoplasia, malignant blood disease, HIV, or other major disease (e.g., systemic fungal infection) * Subject with recurrent porphyria, untreated epilepsy, coronary insufficiency, ventricular rhythm disorders, severe hypertension, obstructive cardiomyopathy, hyperthyroidism * Subject with any skin or systemic disease (acute and/or chronic), in the previous year, likely to interfere with the measured parameters or to put the subject to an undue risk * Subject with known history of or suffering from autoimmune disease and/or immune deficiency * Subject with current cutaneous inflammatory or infectious processes (e.g., acne, herpes, mycosis, papilloma, chronic eczema, atopic dermatitis …), abscess, unhealed wound, or a cancerous or precancerous lesion on the face * Subject with multiple allergies, anaphylactic shock history, evolutive allergic pathologies, history of granulomatous diseases * Subject with known hypersensitivity to chlorhexidine * Subject having history of allergy or hypersensitivity to one of the components of the tested device, like hyaluronic acid, lidocaine or other amine-type local anaesthetics. polysaccharides of edible mushrooms * Subject predisposed to keloids or hypertrophic scarring * Subject with coagulation and/or homeostasis disorders * Subject with evidence of lymphatic or venous stasis or serious blood disorders * Subject with pigmentation disorders * Subject with history of Streptococcus disease (recurrent sore throats, acute rheumatic fever) * Subjects with congenital methemoglobinemia or receiving concomitant treatment with methaemoglobin-inducing agents * For subject injected in the chin: subject with clinically significant malocclusion (severe overbite), having dentures and/or any device covering the palate that would interfere with visual assessment of the chin area * Subject with tattoos, piercings, facial hairs mole or scar that would interfere with visual assessment on the injected area * Subject with symptoms consistent with COVID-19 or suffering from ongoing symptoms from previous COVID-19 infection * Subject under anti-coagulant treatment (such as aspirin, nonsteroidal anti-inflammatory drugs) or treatment liable to interfere with the healing process or hemostasis, within 1 month prior to injection, and one-month post-injection. * Subject with a treatment that reduces or inhibits hepatic metabolism (cimetidine, beta-blockers, etc..) * Subject having received a vaccine within 21 days prior to injection or planning to do in the 14 days post-injection * Subject having received dental care within 6 weeks prior to the study or planning to have dental care within 6 weeks post-injection * Subject receiving any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject to undue risk * Subject undergoing a topical (on the face) or systemic treatment: 1. anti-inflammatory medication and/or antihistamines within 2 weeks prior to injection, and 1 month post-injection 2. corticosteroids within 1 month prior to injection, and 1-month post-injection 3. retinoids and/or immunosuppressors within 3 months prior to injection and during the study * Intensive exposure to sunlight or UV-rays within the previous month and/or planning to do so during the study * Heavy smoker (subject who reports smoking 10 or more cigarettes per day); * Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day)

Outcomes

Primary Outcomes

Assessment of improvement of KIO017 device range on GAIS (Global Aesthetic Improvement Scale)

Proportion of indications having an improvement with the overall KIO017 range of devices as assessed by the investigator in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))

Time frame: The measurement is performed on Month 3 after the injection

Assessment of Safety

Assessment of number and percentage of subjects with Adverse Device Effects (ADEs). ADEs are defined as any adverse event related to the use of the investigational medical device.

Time frame: Evaluation is performed on the Month 1 after injection.

Secondary Outcomes

Assessment of proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the investigator in live

Time frame: Measurement of improvement after injection on the Month 1, Month 6, Month 9, Month 12, Month 18 and Month 24

Assessment of each product and proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the investigator in live

For each product, proportion of indications having an improvement with each KIO017 device as assessed by the investigator in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))

Time frame: Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24

Assessment of each indication and proportion of subjects having an improvement on GAIS (Global Aesthetic Improvement Scale) by the investigator in live

For each indication, proportion of subjects having an improvement with each KIO017 device as assessed by the investigator in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))

Time frame: Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24

Assessment of proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the subject in live

Proportion of indications having an improvement with the overall KIO017 range of devices as assessed by the subject in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))

Time frame: Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24

Assessment of each product, proportion of indications having an improvement on GAIS (Global Aesthetic Improvement Scale) by the subject in live

For each product, proportion of indications having an improvement with each KIO017 device as assessed by the subject in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))

Time frame: Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24

Assessment of each indication, proportion of subjects having an improvement on GAIS (Global Aesthetic Improvement Scale) by the subject in live

For each indication, proportion of subjects having an improvement with each KIO017 device as assessed by the subject in live using the GAIS (in 5 points from "worse" (5) to very much improved" (1))

Time frame: Measurement of improvement after injection on the Month 1, Month 3, Month 6, Month 9, Month 12, Month 18 and Month 24

Assessment of improvement on Bazin Ptosis of the Lower part of the Face Scale (PLFS)

Change from baseline and proportion of subjects with improvement based on Bazin Ptosis of the Lower part of the Face Scale (PLFS) for the subjects injected in jawline with KIO017-1 (in 6 grades: from grade 0 to grade 5)